Sol-Gel Technologies Ltd. (SLGL) touched a new 52-week high of $18.66 yesterday, reflecting growing investor confidence. With a key clinical trial milestone on the horizon, it will be worth watching whether the stock's upward momentum can be sustained.
This dermatology company focuses on skin diseases for which there are no approved therapeutics. It has successfully developed two FDA-approved products, EPSOLAY and TWYNEO, and is advancing two drug candidates in clinical development: SGT-610 (topical Patidegib) and SGT-210 (topical Erlotinib).
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.